Ari­ad’s briga­tinib scores 15.6 month PFS rate; Neurim­mune backs ALS spin­out

Ari­ad Phar­ma­ceu­ti­cals is re­port­ing that its ALK in­hibitor briga­tinib scored a 55% ob­jec­tive re­sponse rate in among pa­tients tak­ing 180 mg. In this same arm the PFS rate was a me­di­an 15.6 months. “These up­dat­ed AL­TA tri­al da­ta show that with ad­di­tion­al fol­low-up, me­di­an pro­gres­sion-free sur­vival from briga­tinib giv­en post-crizo­tinib is now 15.6 months, and that this is the same whether as­sessed by the in­ves­ti­ga­tors or an in­de­pen­dent re­view com­mit­tee,” said D. Ross Camidge, MD, PhD., di­rec­tor of tho­racic on­col­o­gy at the Uni­ver­si­ty of Col­orado.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.